- Home
- EPAM vs BLCO Comparison
EPAM vs BLCO Comparison
Compare EPAM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | BLCO |
|---|---|---|
| Founded | 1993 | 1853 |
| Country | United States | Canada |
| Employees | 62850 | N/A |
| Industry | EDP Services | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EPAM | BLCO |
|---|---|---|
| Price | $98.11 | $15.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $196.21 | $18.45 |
| AVG Volume (30 Days) | ★ 1.9M | 452.0K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | $1,450,448,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $8.30 | $8.65 |
| Revenue Next Year | $7.17 | $5.59 |
| P/E Ratio | $64.00 | ★ N/A |
| Revenue Growth | ★ 25.02 | 6.47 |
| 52 Week Low | $89.25 | $11.44 |
| 52 Week High | $222.53 | $18.92 |
Technical Indicators
Market Signals| Indicator | EPAM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 40.79 |
| Support Level | $89.25 | $15.20 |
| Resistance Level | $106.77 | $15.57 |
| Average True Range (ATR) | 5.37 | 0.36 |
| MACD | 1.06 | -0.09 |
| Stochastic Oscillator | 36.98 | 35.60 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.